The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Treatment of Fabry’s Disease with the Pharmacologic Chaperone Migalastat
Open accessAbstract
BACKGROUND: Fabry's disease, an X-linked disorder of lysosomal α-galactosidase deficiency, leads to substrate accumulation in multiple organs. Migalastat, an oral pharmacologic chaperone, stabilizes specific mutant forms of α-galactosidase, increasing enzyme trafficking to lysosomes. METHODS: The initial assay of mutant α-galactosidase forms that we used to categorize 67 patients with Fabry's disease for randomization to 6 months of double-blind migalastat or placebo (stage 1), followed by open-label migalastat from 6 to 12 months (stage 2) plus an additional year, had certain limitations. Before unblinding, a new, validated assay showed that 50 of the 67 participants had mutant α-galactosidase forms suitable for targeting by migalastat. The primary end point was the percentage of patients who had a response (≥50% reduction in the number of globotriaosylceramide inclusions per kidney interstitial capillary) at 6 months. We assessed safety along with disease substrates and renal, cardiovascular, and patient-reported outcomes. RESULTS: The primary end-point analysis, involving patients with mutant α-galactosidase forms that were suitable or not suitable for migalastat therapy, did not show a significant treatment effect: 13 of 32 patients (41%) who received migalastat and 9 of 32 patients (28%) who received placebo had a response at 6 months (P=0.30). Among patients with suitable mutant α-galactosidase who received migalastat for up to 24 months, the annualized changes from baseline in the estimated glomerular filtration rate (GFR) and measured GFR were -0.30±0.66 and -1.51±1.33 ml per minute per 1.73 m(2) of body-surface area, respectively. The left-ventricular-mass index decreased significantly from baseline (-7.7 g per square meter; 95% confidence interval [CI], -15.4 to -0.01), particularly when left ventricular hypertrophy was present (-18.6 g per square meter; 95% CI, -38.2 to 1.0). The severity of diarrhea, reflux, and indigestion decreased. CONCLUSIONS: Among all randomly assigned patients (with mutant α-galactosidase forms that were suitable or not suitable for migalastat therapy), the percentage of patients who had a response at 6 months did not differ significantly between the migalastat group and the placebo group. (Funded by Amicus Therapeutics; ClinicalTrials.gov numbers, NCT00925301 [study AT1001-011] and NCT01458119 [study AT1001-041].).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1992) · PubMed · Cited by 33,716
The MOS 36-ltem Short-Form Health Survey (SF-36): I. Conceptual Framework and Item Selection
Ware, J. E., & Sherbourne, C. D. (1992) · Medical Care · doi:10.1097/00005650-199206000-00002 · Cited by 30,033
A New Equation to Estimate Glomerular Filtration Rate
Levey, A. S., Stevens, L. A., Schmid, C. H., Zhang, Y. (., Castro, A. F., Feldman, H. I., Kusek, J. W., Eggers, P., Van Lente, F., Greene, T., et al. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-150-9-200905050-00006 · Cited by 25,603
Pain assessment: global use of the Brief Pain Inventory.
Cs, C., & Km, R. (1994) · PubMed · Cited by 5,421
Svedlund, J., Sj�din, I., & Dotevall, G. (1988) · Digestive Diseases and Sciences · doi:10.1007/bf01535722 · Cited by 1,468
Germain, D. P. (2010) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-5-30 · Cited by 1,198
Self-citationEnzymatic Defect in Fabry's Disease: Ceramidetrihexosidase Deficiency
Brady, R. O., Gal, A. E., Bradley, R. M., Martensson, E., Warshaw, A. L., & Laster, L. (1967) · New England Journal of Medicine · doi:10.1056/nejm196705252762101 · Cited by 1,053
Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey
Mehta, A., Ricci, R., Widmer, U., Dehout, F., Garcia de Lorenzo, A., Kampmann, C., Linhart, A., Sunder‐Plassmann, G., Ries, M., & Beck, M. (2004) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2004.01309.x · Cited by 848
Revicki, D. A., Wood, M., Wiklund, I., & Crawley, J. (1997) · Quality of Life Research · doi:10.1023/a:1008841022998 · Cited by 617
Fan, J.-Q., Ishii, S., Asano, N., & Suzuki, Y. (1999) · Nature Medicine · doi:10.1038/4801 · Cited by 614
Agalsidase-Beta Therapy for Advanced Fabry Disease: A Randomized Trial
Banikazemi, M., Bultas, J., Waldek, S., Wilcox, W. R., Whitley, C. B., McDonald, M., Finkel, R., Packman, S., Bichet, D. G., Warnock, D. G., et al. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-146-2-200701160-00148 · Cited by 569
Self-citationWeidemann, F., Niemann, M., Breunig, F., Herrmann, S., Beer, M., Störk, S., Voelker, W., Ertl, G., Wanner, C., & Strotmann, J. (2009) · Circulation · doi:10.1161/circulationaha.108.794529 · Cited by 488
Eng, C. M., Fletcher, J., Wilcox, W. R., Waldek, S., Scott, C. R., Sillence, D. O., Breunig, F., Charrow, J., Germain, D. P., Nicholls, K., et al. (2007) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-007-0521-2 · Cited by 380
Self-citationSchiffmann, R., Warnock, D. G., Banikazemi, M., Bultas, J., Linthorst, G. E., Packman, S., Sorensen, S. A., Wilcox, W. R., & Desnick, R. J. (2009) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfp031 · Cited by 368
Self-citationWaldek, S., Patel, M. R., Banikazemi, M., Lemay, R., & Lee, P. (2009) · Genetics in Medicine · doi:10.1097/gim.0b013e3181bb05bb · Cited by 353
Self-citationEnzyme replacement and enhancement therapies for lysosomal diseases
Desnick, R. J. (2004) · Journal of Inherited Metabolic Disease · doi:10.1023/b:boli.0000031101.12838.c6 · Cited by 222
Ries, M., Gupta, S., Moore, D. F., Sachdev, V., Quirk, J. M., Murray, G. J., Rosing, D. R., Robinson, C., Schaefer, E., Gal, A., et al. (2005) · Pediatrics · doi:10.1542/peds.2004-1678 · Cited by 209
Self-citationHoffmann, B., Schwarz, M., Mehta, A., & Keshav, S. (2007) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2007.08.012 · Cited by 179
Warnock, D. G., Ortiz, A., Mauer, M., Linthorst, G. E., Oliveira, J. P., Serra, A. L., Marodi, L., Mignani, R., Vujkovac, B., Beitner-Johnson, D., et al. (2012) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfr420 · Cited by 176
Self-citationBenjamin, E. R., Flanagan, J. J., Schilling, A., Chang, H. H., Agarwal, L., Katz, E., Wu, X., Pine, C., Wustman, B., Desnick, R. J., et al. (2009) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-009-1077-0 · Cited by 173
Self-citationCardiovascular Events in Patients With Fabry Disease
Patel, M. R., Cecchi, F., Cizmarik, M., Kantola, I., Linhart, A., Nicholls, K., Strotmann, J., Tallaj, J., Tran, T. C., West, M. L., et al. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.11.018 · Cited by 173
Self-citationYam, G. H.-F., Zuber, C., & Roth, J. (2005) · The FASEB Journal · doi:10.1096/fj.04-2375com · Cited by 163
Prognostic Indicators of Renal Disease Progression in Adults with Fabry Disease
Wanner, C., Oliveira, J. P., Ortíz, A., Mauer, M. S., Germain, D. P., Linthorst, G. E., Serra, A. L., Maródi, L., Mignani, R., Cianciaruso, B., et al. (2010) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.04340510 · Cited by 157
Self-citationKhanna, R., Soska, R., Lun, Y., Feng, J., Frascella, M., Young, B. L., Brignol, N., Pellegrino, L. J., Sitaraman, S., Desnick, R. J., et al. (2009) · Molecular Therapy · doi:10.1038/mt.2009.220 · Cited by 149
Self-citationMolecular basis of fabry disease: Mutations and polymorphisms in the human α-galactosidase A gene
Eng, C. M., & Desnick, R. J. (1994) · Human Mutation · doi:10.1002/humu.1380030204 · Cited by 142
Sakuraba, H., Oshima, A., Fukuhara, Y., Shimmoto, M., Nagao, Y., Bishop, D. F., Desnick, R. J., & Suzuki, Y. (1990) · PubMed · Cited by 136
Serum-Mediated Inhibition of Enzyme Replacement Therapy in Fabry Disease
Lenders, M., Stypmann, J., Duning, T., Schmitz, B., Brand, S.-M., & Brand, E. (2016) · Journal of the American Society of Nephrology · doi:10.1681/asn.2014121226 · Cited by 133
Bénichou, B., Goyal, S., Sung, C., Norfleet, A. M., & O’Brien, F. (2008) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2008.10.004 · Cited by 109
Germain, D. P., Giugliani, R., Hughes, D. A., Mehta, A. B., Nicholls, K., Barisoni, L. M. C., Jennette, J. C., Bragat, A., Castelli, J. P., Sitaraman, S., et al. (2012) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-7-91 · Cited by 109
Self-citationIshii, S., Sakuraba, H., & Suzuki, Y. (1992) · Human Genetics · doi:10.1007/bf00207037 · Cited by 103
Boutin, M., & Auray‐Blais, C. (2014) · Analytical Chemistry · doi:10.1021/ac404000d · Cited by 85
Wu, X., Katz, E., Valle, M. C. D., Mascioli, K., Flanagan, J. J., Castelli, J. P., Schiffmann, R., Boudes, P. F., Lockhart, D. J., Valenzano, K. J., et al. (2011) · Human Mutation · doi:10.1002/humu.21530 · Cited by 84
Self-citationAnti-α-galactosidase A antibody response to agalsidase beta treatment: Data from the Fabry Registry
Wilcox, W. R., Linthorst, G. E., Germain, D. P., Feldt‐Rasmussen, U., Waldek, S., Richards, S. M., Beitner‐Johnson, D., Cizmarik, M., Cole, J. A., Kingma, W., et al. (2011) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2011.12.006 · Cited by 78
Self-citationPisani, A., Visciano, B., Imbriaco, M., Nuzzi, A. D., Mancini, A., Marchetiello, C., & Riccio, E. (2014) · Clinical Genetics · doi:10.1111/cge.12386 · Cited by 69
Lee, B. H., Heo, S. H., Kim, G.-H., et al. (2010) · Journal of Human Genetics · doi:10.1038/jhg.2010.58 · Cited by 54
Functional studies of new GLA gene mutations leading to conformational fabry disease
Filoni, C., Caciotti, A., Carraresi, L., Cavicchi, C., Parini, R., Antuzzi, D., Zampetti, A., Feriozzi, S., Poisetti, P. G., Garman, S. C., et al. (2009) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2009.11.003 · Cited by 54
Johnson, F. K., Mudd, P. N., Bragat, A., Adera, M., & Boudes, P. F. (2013) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.1 · Cited by 44
Self-citationBarisoni, L. M. C., Jennette, J. C., Colvin, R. B., Sitaraman, S., Bragat, A., Castelli, J. P., Walker, D., & Boudes, P. F. (2012) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2011-0350-oa · Cited by 23
Self-citation
Cited by
Platt, F. M., d’Azzo, A., Davidson, B. L., Neufeld, E. F., & Tifft, C. J. (2018) · Nature Reviews Disease Primers · doi:10.1038/s41572-018-0025-4 · Cited by 1,052
Neufeld, E. F. (1991) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.60.070191.001353 · Cited by 900
Fabry disease revisited: Management and treatment recommendations for adult patients
Ortiz, A., Germain, D. P., Desnick, R. J., Politei, J., Mauer, M., Burlina, A., Eng, C., Hopkin, R. J., Laney, D., Linhart, A., et al. (2018) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2018.02.014 · Cited by 650
Self-citationPharmacological targeting of endoplasmic reticulum stress in disease
Marciniak, S. J., Chambers, J. E., & Ron, D. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00320-3 · Cited by 520
Drug development in the era of precision medicine
Dugger, S. A., Platt, A., & Goldstein, D. B. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.226 · Cited by 493
Metadata
- Authors
- Germain, D. P., Hughes, D. A., Nicholls, K., Bichet, D. G., Giugliani, R., Wilcox, W. R., Feliciani, C., Shankar, S. P., Ezgu, F., Amartino, H., Bratkovic, D., Feldt-Rasmussen, U., Nedd, K., Sharaf El Din, U., Lourenco, C. M., Banikazemi, M., Charrow, J., Dasouki, M., Finegold, D., Giraldo, P., Goker-Alpan, O., Longo, N., Scott, C. R., Torra, R., Tuffaha, A., Jovanovic, A., Waldek, S., Packman, S., Ludington, E., Viereck, C., Kirk, J., Yu, J., Benjamin, E. R., Johnson, F., Lockhart, D. J., Skuban, N., Castelli, J., Barth, J., Barlow, C., & Schiffmann, R.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2016-08-11
- Volume
- 375
- Issue
- 6
- Pages
- 545-555
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2500404244
- Cited by
- 555
- References
- 38
- FWCI
- 34.45
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.